Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia

Neuropsychopharmacology

Volumn 39, Issue 9, 2014, Pages 2170-2178

  Jenkins, Aaron ^a,b   Apud, José A ^a   Zhang, Fengyu ^c   Decot, Heather ^a   Weinberger, Daniel R ^c,d   Law, Amanda J ^e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; NEUREXIN; NEUREXIN 1; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG; ZIPRASIDONE; NERVE CELL ADHESION MOLECULE; NERVE PROTEIN; NEUROLEPTIC AGENT; NRXN1 PROTEIN, HUMAN;

ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; FAMILY STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; NEGATIVE SYNDROME; NEUROPATHOLOGY; PHARMACOGENETICS; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; THINKING; TREATMENT RESPONSE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FAMILY; GENETICS; GENOTYPING TECHNIQUE; PSYCHOLOGICAL RATING SCALE; RISK; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES, NEURONAL; COHORT STUDIES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FAMILY; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MALE; NERVE TISSUE PROTEINS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RISK; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84904463987     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.65     Document Type: Article

References (52)

1. Apud JA, Zhang F, Decot H, Bigos KL, Weinberger DR (2012). Genetic variation in KCNH2 associated with expression in the brain of a unique hERG isoform modulates treatment response in patients with schizophrenia. Am J Psychiatry 169: 725-734.
2. Bassett AS, Marshall CR, Lionel AC, Chow EW, Scherer SW (2008). Copy number variations and risk for schizophrenia in 22q11.2 deletion syndrome. Hum Mol Genet 17: 4045-4053.
3. Bena F, Bruno DL, Eriksson M, van Ravenswaaij-Arts C, Stark Z, Dijkhuizen T et al (2013). Molecular and clinical characterization of 25 individuals with exonic deletions of NRXN1 and comprehensive review of the literature. Am J Med Genet B Neuropsychiatr Genet 162B: 388-403.
4. Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF et al (2007). Novel genes identified in a highdensity genome wide association study for nicotine dependence. Hum Mol Genet 16: 24-35.
5. Bigos KL1, Bies RR, Pollock BG, Lowy JJ, Zhang F, Weinberger DR (2011). Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Mol Psychiatry 16: 620-625.
6. Bigos KL1, Pollock BG, Coley KC, Miller DD, Marder SR, Aravagiri M et al (2008). Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 48: 157-165.
7. Chen X, Shen Y, Zhang F, Chiang C, Pillalamarri V, Blumenthal I et al (2013). Molecular analysis of a deletion hotspot in the NRXN1 region reveals the involvement of short inverted repeats in deletion CNVs. Am J Hum Genet 92: 375-386.
8. Dabell MP, Rosenfeld JA, Bader P, Escobar LF, El-Khechen D, Vallee SE et al (2013). Investigation of NRXN1 deletions: clinical and molecular characterization. Am J Med Genet 161: 717-731.
9. Docampo E, Ribases M, Gratacos M, Bruguera E, Cabezas C, Sanchez-Mora C et al (2012). Association of neurexin 3 polymorphisms with smoking behavior. Genes Brain Behav 11: 704-711.
10. 2+-triggered exocytosis of secretory granules. J Neurosci 26: 10599-10613.
11. Duong L, Klitten LL, Moller RS, Ingason A, Jakobsen KD, Skjodt C et al (2012). Mutations in NRXN1 in a family multiply affected with brain disorders: NRXN1 mutations and brain disorders. Am J Med Genet B Neuropsychiatr Genet 159B: 354-358.
12. Fedorova L, Fedorov A (2003). Introns in gene evolution. Genetica 118: 123-131.
13. Giegling I, Balzarro B, Porcelli S, Schafer M, Hartmann AM, Friedl M et al (2013). Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol. Eur Arch Psychiatry Clin Neurosci 263: 65-74.
14. Grayton HM, Fernandes C, Rujescu D, Collier DA (2012). Copy number variations in neurodevelopmental disorders. Prog Neurobiol 99: 81-91.
15. Hishimoto A, Liu QR, Drgon T, Pletnikova O, Walther D, Zhu XG et al (2007). Neurexin 3 polymorphisms are associated with alcohol dependence and altered expression of specific isoforms. Hum Mol Genet 16: 2880-2891.
16. Ikeda M, Yamanouchi Y, Kinoshita Y, Kitajima T, Yoshimura R, Hashimoto S et al (2008). Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 9: 1437-1443.
17. Ikeda M, Aleksic B, Kirov G, Kinoshita Y, Yamanouchi Y, Kitajima T et al (2010). Copy number variation in schizophrenia in the Japanese population. Biol Psychiatry 67: 283-286.
18. International Schizophrenia Consortium (2008). Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 455: 237-241.
19. Kapur S, Mamo D (2003). Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27: 1081-1090.
20. Kay SR, Opler LA, Spitzer RL, Williams JB, Fiszbein A, Gorelick A (1991). SCID-PANSS: two-tier diagnostic system for psychotic disorders. Compr Psychiatry 32: 355-361.
21. Kirov G, Gumus D, Chen W, Norton N, Georgieva L, Sari M et al (2008). Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet 17: 458-465.
22. Kirov G, Rujescu D, Ingason A, Collier DA, O'Donovan MC, Owen MJ (2009). Neurexin 1 (NRXN1) deletions in schizophrenia. Schizophr Bull 35: 851-854.
23. Law AJ, Wang Y, Sei Y, O'Donnell P, Piantadosi P, Papaleo F et al (2012). Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110delta inhibition as a potential therapeutic strategy. Proc Natl Acad Sci USA 109: 12165-12170.
24. Lett TA, Tiwari AK, Meltzer HY, Lieberman JA, Potkin SG, Voineskos AN et al (2011). The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. Schizophr Res 132: 121-124.
25. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
26. Lotrich FE (2012). The emerging potential of pharmacogenetics in psychiatry. Am J Psychiatry 169: 681-683.
27. Malhotra AK, Zhang JP, Lencz T (2012a). Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatry 17: 760-769.
28. Malhotra AK, Correll CU, Chowdhury NI, Müller DJ, Gregersen PK, Lee AT et al (2012b). Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry 69: 904-912.
29. Missler M, Fernandez-Chacon R, Sudhof TC (1998). The making of neurexins. J Neurochem 71: 1339-1347.
30. 2+ channels to synaptic vesicle exocytosis. Nature 423: 939-948.
31. Moller RS, Weber YG, Klitten LL, Trucks H, Muhle H, Kunz WS et al (2013). Exon-disrupting deletions of NRXN1 in idiopathic generalized epilepsy. Epilepsia 54: 256-264.
32. Muhleisen TW, Basmanav FB, Forstner AJ, Mattheisen M, Priebe L, Herms S et al (2011). Resequencing and follow-up of neurexin 1 (NRXN1) in schizophrenia patients. Schizophr Res 127: 35-40.
33. Need AC, Keefe RS, Ge D, Grossman I, Dickson S, McEvoy JP et al (2009). Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet 17: 946-957.
34. Nussbaum J, Xu Q, Payne TJ, Ma JZ, Huang W, Gelernter J et al (2008). Significant association of the neurexin-1 gene (NRXN1) with nicotine dependence in European- and African-American smokers. Hum Mol Genet 17: 1569-1577.
35. Owen MJ (2012). Implications of genetic findings for understanding schizophrenia. Schizophr Bull 38: 904-907.
36. Prathikanti S, Weinberger DR (2005). Psychiatric genetics-the new era: genetic research and some clinical implications. Br Med Bull 73-74: 107-122.
37. Ripke, Chambert K, Moran JL, Kähler AK, Akterin S, Bergen SE et al (2013). Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 45: 1150-1159.
38. Rowen L, Young J, Birditt B, Kaur A, Madan A, Philipps DL et al (2002). Analysis of the human neurexin genes: alternative splicing and the generation of protein diversity. Genomics 79: 587-597.
39. Rujescu D, Ingason A, Cichon S, Pietilainen OP, Barnes MR, Toulopoulou T et al (2009). Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet 18: 988-996.
40. Shepard S, McCreary M, Fedorov A (2009). The peculiarities of large intron splicing in animals. PLoS One 4: e7853.
41. Snyder SH (1981). Dopamine receptors, neuroleptics, and schizophrenia. Am J Psychiatry 138: 460-464.
42. Souza RP, Romano-Silva MA, Lieberman JA, Meltzer HY, Wong AH, Kennedy JL (2008). Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl) 200: 177-186.
43. Souza RP, Meltzer HY, Lieberman JA, Le FB, Kennedy JL (2010). Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response. Hum Psychopharmacol 25: 582-585.
44. Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S et al (2008). Large recurrent microdeletions associated with schizophrenia. Nature 455: 232-236.
45. Sudhof TC (2008). Neuroligins and neurexins link synaptic function to cognitive disease. Nature 455: 903-911.
46. Sullivan PF, Daly MJ, O'Donovan M (2012). Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet 13: 537-551.
47. Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS et al (2008). Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 14: 1144-1144.
48. Swaminathan S, Shen L, Kim S, Inlow M, West JD, Faber KM et al (2012). Analysis of copy number variation in Alzheimer's disease: the NIALOAD/ NCRAD Family Study. Curr Alzheimer Res 9: 801-814.
49. Varoqueaux F, Aramuni G, Rawson RL, Mohrmann R, Missler M, Gottmann K et al (2006). Neuroligins determine synapse maturation and function. Neuron 51: 741-754.
50. Weinberger DR (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44: 660-669.
51. Zhang C, Atasoy D, Arac D, Yang X, Fucillo MV, Robison AJ et al (2010). Neurexins physically and functionally interact with GABA(A) receptors. Neuron 66: 403-416.
52. Zhang JP, Lencz T, Malhotra AK (2010). D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 167: 763-772.